CLINICAL_TRIALS
trial_result
· 2019-11-26
Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH [Phase 2]
Summary
Phase 2 trial update for LMB763 in non-alcoholic steatohepatitis (NASH) has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Non-alcoholic Steatohepatitis NASH | Phase 2 | Status: TERMINATED | Results posted: 2019-11-26